Archive for the ‘Regulatory Medical Writing’ Category

A New Anchor in RRMM: Decoding the Practice-Changing MajesTEC-3 Data for Tec-Dara

Posted by Michael A. S. Guth on January 8th, 2026

The MajesTEC-3 results for teclistamab + daratumumab (Tec-Dara)ย in relapsed/refractory multiple myeloma (RRMM) aren’t just an incremental gainโ€”they represent a potential paradigm shift. The FDA’s concurrent award of aย priority review voucherย underscores its transformative potential. Let’s break down the data that’s changing the standard of care: ๐Ÿ”ฌ Unprecedented Efficacy in the 1-3 Prior Lines Setting: โ€ขย PFS:ย Hazard Ratio […]

Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on A New Anchor in RRMM: Decoding the Practice-Changing MajesTEC-3 Data for Tec-Dara
Read More »

One Drug, Two Paths: Decoding Novartis’s Ianalumab Strategy

Posted by Michael A. S. Guth on January 8th, 2026

Following up on my last post: the key to understanding a drug’s potential isn’t just its mechanismโ€”it’s how the sponsor chooses to prove it. Comparing the ianalumab trials side-by-side reveals a brilliant, bifurcated strategy. Trial Aspect Sjรถgren’s (NEPTUNUS-1) Refractory ITP (Phase 2) Phase Pivotal Phase 3 Signal-seeking Phase 2 Design Randomized, Double-blind, Placebo-controlled Open-label, Single-Arm […]

Posted in Regulatory Medical Writing Comments Off on One Drug, Two Paths: Decoding Novartis’s Ianalumab Strategy
Read More »

Why is the same drug ๐ˆ๐š๐ง๐š๐ฅ๐ฎ๐ฆ๐š๐› being tested in Sjรถgren’s Syndrome and Immune Thrombocytopenia?

Posted by Michael A. S. Guth on January 8th, 2026

๐–๐ก๐ฒ ๐ข๐ฌ ๐ญ๐ก๐ž ๐ฌ๐š๐ฆ๐ž ๐๐ซ๐ฎ๐  ๐›๐ž๐ข๐ง๐  ๐ญ๐ž๐ฌ๐ญ๐ž๐ ๐ข๐ง ๐’๐ฃรถ๐ ๐ซ๐ž๐ง’๐ฌ ๐’๐ฒ๐ง๐๐ซ๐จ๐ฆ๐ž ๐š๐ง๐ ๐ˆ๐ฆ๐ฆ๐ฎ๐ง๐ž ๐“๐ก๐ซ๐จ๐ฆ๐›๐จ๐œ๐ฒ๐ญ๐จ๐ฉ๐ž๐ง๐ข๐š? ๐ˆ’๐ฏ๐ž ๐›๐ž๐ž๐ง ๐๐ข๐ ๐ ๐ข๐ง๐  ๐ข๐ง๐ญ๐จ ๐ญ๐ก๐ž ๐œ๐ฅ๐ข๐ง๐ข๐œ๐š๐ฅ ๐ฉ๐ข๐ฉ๐ž๐ฅ๐ข๐ง๐ž ๐Ÿ๐จ๐ซ ๐ง๐จ๐ฏ๐ž๐ฅ ๐š๐ฎ๐ญ๐จ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ž ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ข๐ž๐ฌ, ๐š๐ง๐ ๐๐จ๐ฏ๐š๐ซ๐ญ๐ข๐ฌ’๐ฌ ๐๐ž๐ฏ๐ž๐ฅ๐จ๐ฉ๐ฆ๐ž๐ง๐ญ ๐จ๐Ÿ ๐ข๐š๐ง๐š๐ฅ๐ฎ๐ฆ๐š๐› (๐•๐€๐˜๐Ÿ•๐Ÿ‘๐Ÿ”) ๐œ๐š๐ฎ๐ ๐ก๐ญ ๐ฆ๐ฒ ๐ž๐ฒ๐ž. ๐ˆ๐ญ’๐ฌ ๐š ๐๐€๐…๐…-๐‘ ๐ข๐ง๐ก๐ข๐›๐ข๐ญ๐จ๐ซ ๐ฐ๐ข๐ญ๐ก ๐š ๐๐ฎ๐š๐ฅ ๐ฆ๐ž๐œ๐ก๐š๐ง๐ข๐ฌ๐ฆ: ๐›๐ฅ๐จ๐œ๐ค๐ข๐ง๐  ๐-๐œ๐ž๐ฅ๐ฅ ๐ฌ๐ฎ๐ซ๐ฏ๐ข๐ฏ๐š๐ฅ ๐ฌ๐ข๐ ๐ง๐š๐ฅ๐ฌ ๐š๐ง๐ ๐๐ž๐ฉ๐ฅ๐ž๐ญ๐ข๐ง๐  ๐ฆ๐š๐ญ๐ฎ๐ซ๐ž ๐-๐œ๐ž๐ฅ๐ฅ๐ฌ. ๐“๐ก๐ž ๐ข๐ง๐ญ๐ž๐ซ๐ž๐ฌ๐ญ๐ข๐ง๐  ๐ฉ๐š๐ซ๐ญ? ๐๐จ๐ฏ๐š๐ซ๐ญ๐ข๐ฌ ๐ข๐ฌ ๐ซ๐ฎ๐ง๐ง๐ข๐ง๐  […]

Posted in Regulatory Medical Writing Comments Off on Why is the same drug ๐ˆ๐š๐ง๐š๐ฅ๐ฎ๐ฆ๐š๐› being tested in Sjรถgren’s Syndrome and Immune Thrombocytopenia?
Read More »

๐…๐ซ๐จ๐ฆ ๐€๐ฌ๐ฌ๐ข๐ฌ๐ญ๐š๐ง๐œ๐ž ๐ญ๐จ ๐€๐ ๐ž๐ง๐œ๐ฒ: ๐–๐ก๐ฒ ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐‚๐š๐ซ๐ž ๐†๐ข๐š๐ง๐ญ๐ฌ ๐๐ž๐ž๐ ๐‚๐จ๐ฆ๐›๐ข๐ง๐ž๐ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ/๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ ๐€๐ซ๐ž๐š/๐€๐ˆ ๐’๐ค๐ข๐ฅ๐ฅ๐ž๐ ๐“๐š๐ฅ๐ž๐ง๐ญ

Posted by Michael A. S. Guth on January 3rd, 2026

๐“๐ก๐ž “๐๐ฎ๐ซ๐ฉ๐ฅ๐ž ๐’๐ช๐ฎ๐ข๐ซ๐ซ๐ž๐ฅ” ๐“๐š๐ฅ๐ž๐ง๐ญ ๐†๐š๐ฉ Recruiters often call this the โ€œpurple squirrelโ€ profile: a “unicorn” blending deep regulatory strategy, therapeutic area such as neurology research expertise, with a fundamental understanding of AI application.

Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐…๐ซ๐จ๐ฆ ๐€๐ฌ๐ฌ๐ข๐ฌ๐ญ๐š๐ง๐œ๐ž ๐ญ๐จ ๐€๐ ๐ž๐ง๐œ๐ฒ: ๐–๐ก๐ฒ ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐‚๐š๐ซ๐ž ๐†๐ข๐š๐ง๐ญ๐ฌ ๐๐ž๐ž๐ ๐‚๐จ๐ฆ๐›๐ข๐ง๐ž๐ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ/๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ ๐€๐ซ๐ž๐š/๐€๐ˆ ๐’๐ค๐ข๐ฅ๐ฅ๐ž๐ ๐“๐š๐ฅ๐ž๐ง๐ญ
Read More »

Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy

Posted by Michael A. S. Guth on January 3rd, 2026

Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy In my independent review of the CARES-310 trial (Camrelizumab-Rivoceranib), I analyzed a common pitfall in modern drug development: the reliance on 16-week primary endpoints to justify long-term therapeutic narratives. While a 16-week data cut can deliver a clean p-value for a regulatory […]

Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy
Read More »

From Jargon to Governance: A 3-Part Blueprint for Trustworthy AI in Healthcare. The ISO AI Governance Trilogy for Pharma: Implement, Understand, and Lead.

Posted by Michael A. S. Guth on January 2nd, 2026

Implement AI. Understand AI. Govern AI. Your ISO Framework for Clinical Innovation. Beyond the Black Box: The ISO Framework for Ethical AI in Life Sciences. AI in Pharma? Master the ISO Playbook. (Implement. Understand. Govern.) ๐‡๐ž๐š๐๐ฅ๐ข๐ง๐ž: ๐๐ฎ๐ข๐ฅ๐๐ข๐ง๐  ๐“๐ซ๐ฎ๐ฌ๐ญ ๐ข๐ง ๐€๐ˆ-๐ƒ๐ซ๐ข๐ฏ๐ž๐ง ๐‚๐ฅ๐ข๐ง๐ข๐œ๐š๐ฅ ๐“๐ซ๐ข๐š๐ฅ๐ฌ: ๐–๐ก๐ฒ ๐˜๐จ๐ฎ๐ซ ๐Ž๐ซ๐ ๐š๐ง๐ข๐ณ๐š๐ญ๐ข๐จ๐ง ๐๐ž๐ž๐๐ฌ ๐š๐ง ๐€๐ˆ๐Œ๐’ (๐€๐ˆ ๐Œ๐š๐ง๐š๐ ๐ž๐ฆ๐ž๐ง๐ญ ๐’๐ฒ๐ฌ๐ญ๐ž๐ฆ) ๐“๐ก๐ž ๐ฉ๐ซ๐จ๐ฆ๐ข๐ฌ๐ž ๐จ๐Ÿ ๐€๐ˆ […]

Posted in AI Governance, Regulatory Medical Writing Comments Off on From Jargon to Governance: A 3-Part Blueprint for Trustworthy AI in Healthcare. The ISO AI Governance Trilogy for Pharma: Implement, Understand, and Lead.
Read More »

๐€๐ซ๐ž ๐ฐ๐ž ๐ฎ๐ง๐ฅ๐จ๐œ๐ค๐ข๐ง๐  ๐ญ๐ก๐ž ๐Ÿ๐ฎ๐ฅ๐ฅ ๐ฉ๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐จ๐Ÿ ๐ฆ๐š๐ฆ๐ฆ๐š๐ฅ๐ข๐š๐ง ๐œ๐ž๐ฅ๐ฅ ๐ž๐ง๐ ๐ข๐ง๐ž๐ž๐ซ๐ข๐ง๐ ?

Posted by Michael A. S. Guth on December 18th, 2025

๐‡๐ž๐š๐๐ฅ๐ข๐ง๐ž: ๐€๐ซ๐ž ๐ฐ๐ž ๐ฎ๐ง๐ฅ๐จ๐œ๐ค๐ข๐ง๐  ๐ญ๐ก๐ž ๐Ÿ๐ฎ๐ฅ๐ฅ ๐ฉ๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐จ๐Ÿ ๐ฆ๐š๐ฆ๐ฆ๐š๐ฅ๐ข๐š๐ง ๐œ๐ž๐ฅ๐ฅ ๐ž๐ง๐ ๐ข๐ง๐ž๐ž๐ซ๐ข๐ง๐ ? ๐ƒ๐ซ๐ฎ๐  ๐๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ ๐ข๐ฌ๐ง’๐ญ ๐ฃ๐ฎ๐ฌ๐ญ ๐š๐›๐จ๐ฎ๐ญ ๐Ÿ๐ข๐ง๐๐ข๐ง๐  ๐š ๐ญ๐š๐ซ๐ ๐ž๐ญ; ๐ข๐ญ’๐ฌ ๐š๐›๐จ๐ฎ๐ญ ๐›๐ฎ๐ข๐ฅ๐๐ข๐ง๐  ๐ญ๐ก๐ž ๐ซ๐ข๐ ๐ก๐ญ ๐ญ๐จ๐จ๐ฅ ๐ญ๐จ ๐ก๐ข๐ญ ๐ข๐ญ. ๐“๐ก๐š๐ญ’๐ฌ ๐ฐ๐ก๐ž๐ซ๐ž ๐ฉ๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐ฉ๐ซ๐จ๐ญ๐ž๐ข๐ง ๐ž๐ฑ๐ฉ๐ซ๐ž๐ฌ๐ฌ๐ข๐จ๐ง ๐š๐ง๐ ๐š๐๐ฏ๐š๐ง๐œ๐ž๐ ๐ฆ๐š๐ฆ๐ฆ๐š๐ฅ๐ข๐š๐ง ๐œ๐ž๐ฅ๐ฅ ๐ž๐ง๐ ๐ข๐ง๐ž๐ž๐ซ๐ข๐ง๐  ๐œ๐จ๐ฆ๐ž ๐ข๐ง. ๐†๐จ๐ง๐ž ๐š๐ซ๐ž ๐ญ๐ก๐ž ๐๐š๐ฒ๐ฌ ๐จ๐Ÿ ๐ฃ๐ฎ๐ฌ๐ญ ๐ ๐ž๐ญ๐ญ๐ข๐ง๐  ๐š๐ง๐ฒ ๐ฉ๐ซ๐จ๐ญ๐ž๐ข๐ง. ๐“๐จ๐๐š๐ฒ, ๐ข๐ญ’๐ฌ ๐š๐›๐จ๐ฎ๐ญ: โ–ถ๏ธ ๐…๐ฎ๐ง๐œ๐ญ๐ข๐จ๐ง๐š๐ฅ ๐‚๐จ๐ฆ๐ฉ๐ฅ๐ž๐ฑ๐ข๐ญ๐ฒ: […]

Posted in Regulatory Medical Writing Comments Off on ๐€๐ซ๐ž ๐ฐ๐ž ๐ฎ๐ง๐ฅ๐จ๐œ๐ค๐ข๐ง๐  ๐ญ๐ก๐ž ๐Ÿ๐ฎ๐ฅ๐ฅ ๐ฉ๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐จ๐Ÿ ๐ฆ๐š๐ฆ๐ฆ๐š๐ฅ๐ข๐š๐ง ๐œ๐ž๐ฅ๐ฅ ๐ž๐ง๐ ๐ข๐ง๐ž๐ž๐ซ๐ข๐ง๐ ?
Read More »

Beyond the Nomogram: Achieving Pharmacokinetic Targets to Combat Superbugs

Posted by Michael A. S. Guth on December 13th, 2025

Antimicrobial resistance (AMR) is perhaps the most pressing global health crisis of our time. The pipeline for new antibiotics is slow, meaning that our most powerful tool in the fight against “superbugs” is optimizing the use of the drugs we already possess. The traditional approach to antibiotic dosingโ€”relying on standard, one-size-fits-all nomogramsโ€”is increasingly inadequate because […]

Posted in Regulatory Medical Writing Comments Off on Beyond the Nomogram: Achieving Pharmacokinetic Targets to Combat Superbugs
Read More »

๐๐š๐ฏ๐ข๐ ๐š๐ญ๐ข๐ง๐  ๐€๐ˆ ๐‘๐ข๐ฌ๐ค ๐ข๐ง ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž: ๐ˆ๐ญ ๐’๐ญ๐š๐ซ๐ญ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐š ๐…๐ซ๐š๐ฆ๐ž๐ฐ๐จ๐ซ๐ค

Posted by Michael A. S. Guth on December 12th, 2025

๐‡๐ž๐š๐๐ฅ๐ข๐ง๐ž: ๐๐š๐ฏ๐ข๐ ๐š๐ญ๐ข๐ง๐  ๐€๐ˆ ๐‘๐ข๐ฌ๐ค ๐ข๐ง ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž: ๐ˆ๐ญ ๐’๐ญ๐š๐ซ๐ญ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐š ๐…๐ซ๐š๐ฆ๐ž๐ฐ๐จ๐ซ๐ค ๐€๐ˆ ๐š๐ง๐ ๐Œ๐š๐œ๐ก๐ข๐ง๐ž ๐‹๐ž๐š๐ซ๐ง๐ข๐ง๐  ๐š๐ซ๐ž ๐ญ๐ซ๐š๐ง๐ฌ๐Ÿ๐จ๐ซ๐ฆ๐ข๐ง๐  ๐ฆ๐ž๐๐ข๐œ๐š๐ฅ ๐๐ž๐ฏ๐ข๐œ๐ž๐ฌ, ๐จ๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ง๐  ๐ข๐ง๐œ๐ซ๐ž๐๐ข๐›๐ฅ๐ž ๐ฉ๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐Ÿ๐จ๐ซ ๐๐ข๐š๐ ๐ง๐จ๐ฌ๐ข๐ฌ, ๐ญ๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ, ๐š๐ง๐ ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ ๐œ๐š๐ซ๐ž. ๐๐ฎ๐ญ ๐ฐ๐ข๐ญ๐ก ๐ญ๐ก๐ข๐ฌ ๐ฉ๐จ๐ฐ๐ž๐ซ ๐œ๐จ๐ฆ๐ž๐ฌ ๐š ๐œ๐ซ๐ข๐ญ๐ข๐œ๐š๐ฅ ๐ช๐ฎ๐ž๐ฌ๐ญ๐ข๐จ๐ง: ๐‡๐จ๐ฐ ๐๐จ ๐ฐ๐ž ๐ž๐ง๐ฌ๐ฎ๐ซ๐ž ๐ญ๐ก๐ž๐ฌ๐ž “๐›๐ฅ๐š๐œ๐ค ๐›๐จ๐ฑ” ๐ฌ๐ฒ๐ฌ๐ญ๐ž๐ฆ๐ฌ ๐š๐ซ๐ž ๐ฌ๐š๐Ÿ๐ž ๐š๐ง๐ ๐ž๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ข๐ฏ๐ž? ๐„๐ง๐ญ๐ž๐ซ ๐€๐€๐Œ๐ˆ ๐“๐ˆ๐‘๐Ÿ‘๐Ÿ’๐Ÿ—๐Ÿ•๐Ÿ. ๐“๐ก๐ข๐ฌ ๐“๐ž๐œ๐ก๐ง๐ข๐œ๐š๐ฅ ๐ˆ๐ง๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐‘๐ž๐ฉ๐จ๐ซ๐ญ […]

Posted in Regulatory Medical Writing Comments Off on ๐๐š๐ฏ๐ข๐ ๐š๐ญ๐ข๐ง๐  ๐€๐ˆ ๐‘๐ข๐ฌ๐ค ๐ข๐ง ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž: ๐ˆ๐ญ ๐’๐ญ๐š๐ซ๐ญ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐š ๐…๐ซ๐š๐ฆ๐ž๐ฐ๐จ๐ซ๐ค
Read More »

The Dosing Diet: PK/PD Lessons from the Incretin Revolution

Posted by Michael A. S. Guth on December 12th, 2025

The pharmaceutical landscape is being rapidly reshaped by a class of drugs known as incretin mimetics, particularly the new generation of anti-obesity medications (AOMs). While the public focuses on the dramatic weight loss achieved by agonists like semaglutide and tirzepatide, the true marvel of these therapeutics lies in their precise Pharmacokinetics (PK) and Pharmacodynamics (PD).ย These […]

Posted in Regulatory Medical Writing Comments Off on The Dosing Diet: PK/PD Lessons from the Incretin Revolution
Read More »
« Older Entries
Newer Entries »